Clinical Trial Update: Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating pembrolizumab plus olaparib versus abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Keytruda (Pembrolizumab) (pembrolizumab)
• Lynparza (Olaparib) (Olaparib)
• Xtandi (enzalutamide) (enzalutamide)
• Zytiga (abiraterone acetate) (abiraterone acetate)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Prostatic Neoplasms | Phase 3 | Status: COMPLETED | Results posted: 2023-04-20